Aminoglycoside antibiotics have antibacterial effects on most Enterobacteriaceae, Pseudomonas aeruginosa, some other Pseudomonas, Acinetobacter, Alcaligenes, meningococci, gonococci, influenza bacilli, Yersinia, Campylobacter fetus, Mycobacterium tuberculosis and some Mycobacterium. The mechanism of action is to act on the 30S subunit of bacterial ribosomes and inhibit bacterial protein synthesis. Combination with semi-synthetic penicillins or cephalosporins can achieve synergistic antibacterial effects.

It has an inhibitory effect on a variety of Gram-positive and Gram-negative bacteria in vitro, and has a stronger inhibitory effect on hemolytic Streptococcus, Staphylococcus aureus, Vibrio cholerae, Neisseria meningitidis, Shigella, Salmonella typhi, Corynebacterium diphtheriae, etc. It also has a certain inhibitory effect on amoeba.

It mainly interferes with bacterial folate metabolism, selectively inhibits dihydrofolate reductase, and prevents nucleic acid synthesis.

Activation inhibits the release of pain transmitters from the lateral cord, leading to hyperactivation of intrinsic factor, which binds to the U subtype opioid receptors and inhibits serotonin and norepinephrine, thereby eliminating the pain response.

Aminoglycoside antibiotics are sensitive to most Enterobacteriaceae, influenza bacilli, Brucella, meningococci, gonococci, etc., have certain effects on Staphylococci (methicillin-sensitive strains) and Mycobacterium tuberculosis, and are resistant to most other Gram-positive bacteria such as hemolytic streptococci, Streptococcus pneumoniae, Enterococci and anaerobic bacteria. They inhibit bacterial protein synthesis by binding to the 30S subunit of the bacterial ribosome.

This product is a semi-synthetic aminoglycoside antibiotic with strong antibacterial activity against aerobic Gram-negative bacteria. It has good antibacterial effects on Escherichia coli, Pseudomonas aeruginosa, indole-negative and -positive Proteus, Klebsiella, Acinetobacter, Citrobacter, and some strains of Serratia and Enterobacter. It also has good antibacterial effects on Mycobacterium tuberculosis, atypical mycobacteria and Staphylococcus aureus (enzyme-producing and non-enzyme-producing strains). Other Gram-positive bacteria (including fecal streptococci), anaerobic bacteria, Rickettsia, fungi and viruses are not sensitive to this product. This product is stable to aminoglycoside acetyltransferase AAC (3), and strains that can produce this enzyme and are resistant to kanamycin, gentamicin, tobramycin and sisomicin are sensitive to this product. This product can often achieve synergistic effects when used in combination with beta-lactams. The mechanism of action of this product is to bind to the 30S subunit of the bacterial ribosome and inhibit the synthesis of bacterial proteins. Animal test data indicate that this product has lower ototoxicity than gentamicin and tobramycin, and lower nephrotoxicity than gentamicin.